This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.
SparkCures ID | 1113 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 45 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
Trial Collaborators |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Inclusion Criteria prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT):
Note:. A line of therapy is treatment between diagnosis and progression or between two progressions
Inclusion Criteria prior to Ipilimumab:
Exclusion Criteria:
Exclusion Criteria prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT):
Patients ineligible for therapy with ipilimumab, for example:.
Exclusion Criteria prior to Ipilimumab:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Memorial Sloan Kettering Cancer Center to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors